

# Antony P Martin

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/9280408/antony-p-martin-publications-by-year.pdf>

**Version:** 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

32  
papers

517  
citations

13  
h-index

22  
g-index

35  
ext. papers

732  
ext. citations

3.3  
avg, IF

3.16  
L-index

#	Paper	IF	Citations
32	Willingness to pay for a hypothetical malaria vaccine in Brazil: a cross-sectional study and the implications.. <i>Journal of Comparative Effectiveness Research</i> , <b>2022</b> ,	2.1	1
31	Health state utilities for beta-thalassemia: a time trade-off study.. <i>European Journal of Health Economics</i> , <b>2022</b> , 1	3.6	
30	COMplex mental health PATHways (COMPAT) Study: A mixed methods study to inform an evidence-based service delivery model for people with complex needs: Study protocol.. <i>PLoS ONE</i> , <b>2022</b> , 17, e0264173	3.7	
29	Examining the uptake of predictive BRCA testing in the UK; findings and implications. <i>European Journal of Human Genetics</i> , <b>2021</b> , 29, 699-708	5.3	0
28	Potential approaches for the pricing of cancer medicines across Europe to enhance the sustainability of healthcare systems and the implications. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , <b>2021</b> , 21, 527-540	2.2	11
27	Consumer willingness to pay for a hypothetical Chagas disease vaccine in Brazil: a cross-sectional study and the implications. <i>Journal of Comparative Effectiveness Research</i> , <b>2021</b> , 10, 659-672	2.1	3
26	The Budget Impact of Monoclonal Antibodies Used to Treat Metastatic Colorectal Cancer in Minas Gerais, Brazil. <i>Applied Health Economics and Health Policy</i> , <b>2021</b> , 19, 557-577	3.4	1
25	Evidence-based public policy making for medicines across countries: findings and implications for the future. <i>Journal of Comparative Effectiveness Research</i> , <b>2021</b> , 10, 1019-1052	2.1	7
24	Adult lifetime cost of hemophilia B management in the US: payer and societal perspectives from a decision analytic model. <i>Journal of Medical Economics</i> , <b>2021</b> , 24, 363-372	2.4	3
23	Fixed dose drug combinations - are they pharmaco-economically sound? Findings and implications especially for lower- and middle-income countries. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , <b>2020</b> , 20, 1-26	2.2	33
22	Understanding minimum and ideal factor levels for participation in physical activities by people with haemophilia: An expert elicitation exercise. <i>Haemophilia</i> , <b>2020</b> , 26, 711-717	3.3	9
21	Time to Review Authorisation and Funding for New Cancer Medicines in Europe? Inferences from the Case of Olaratumab. <i>Applied Health Economics and Health Policy</i> , <b>2020</b> , 18, 5-16	3.4	18
20	Ongoing strategies to improve the management of upper respiratory tract infections and reduce inappropriate antibiotic use particularly among lower and middle-income countries: findings and implications for the future. <i>Current Medical Research and Opinion</i> , <b>2020</b> , 36, 301-327	2.5	64
19	Response to the Novel Corona Virus (COVID-19) Pandemic Across Africa: Successes, Challenges, and Implications for the Future. <i>Frontiers in Pharmacology</i> , <b>2020</b> , 11, 1205	5.6	68
18	Impact of a Clinical Pharmacist Intervention on Medicine Costs in Patients with Chronic Obstructive Pulmonary Disease in India. <i>PharmacoEconomics - Open</i> , <b>2020</b> , 4, 331-342	2.1	8
17	Rapid Assessment of the Potential Paucity and Price Increases for Suggested Medicines and Protection Equipment for COVID-19 Across Developing Countries With a Particular Focus on Africa and the Implications. <i>Frontiers in Pharmacology</i> , <b>2020</b> , 11, 588106	5.6	20
16	Economic burden of hemophilia B in the US: a systematic literature review. <i>Journal of Drug Assessment</i> , <b>2019</b> , 8, 28-28	1.5	6

15	Proposal for a regulation on health technology assessment in Europe - opinions of policy makers, payers and academics from the field of HTA. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , <b>2019</b> , 19, 251-261	2.2	19
14	Trends in BRCA testing and socioeconomic deprivation. <i>European Journal of Human Genetics</i> , <b>2019</b> , 27, 1351-1360	5.3	3
13	Systematic review of the methods used in economic evaluations of targeted physical activity and sedentary behaviour interventions. <i>Social Science and Medicine</i> , <b>2019</b> , 232, 156-167	5.1	3
12	Disease State Adaptation Experienced By Patients with Hemophilia: Literature Review and Expert Consensus. <i>Blood</i> , <b>2019</b> , 134, 5801-5801	2.2	1
11	Pricing of oral generic cancer medicines in 25 European countries; findings and implications. <i>GaBI Journal</i> , <b>2019</b> , 8, 49-70	3.1	20
10	Pharmacotherapeutic interventions for bipolar disorder type II: addressing multiple symptoms and approaches with a particular emphasis on strategies in lower and middle-income countries. <i>Expert Opinion on Pharmacotherapy</i> , <b>2019</b> , 20, 2237-2255	4	20
9	Utilization and Expenditure of Anti-cancer Medicines in Kosovo: Findings and Implications. <i>PharmacoEconomics - Open</i> , <b>2018</b> , 2, 423-432	2.1	7
8	Trastuzumab uptake in HER2-positive breast cancer patients: a systematic review and meta-analysis of observational studies. <i>Critical Reviews in Oncology/Hematology</i> , <b>2018</b> , 130, 92-107	7	5
7	Pilot study assessing the direct medical cost of treating patients with cancer in Kenya; findings and implications for the future. <i>Journal of Medical Economics</i> , <b>2018</b> , 21, 878-887	2.4	20
6	Barriers for Access to New Medicines: Searching for the Balance Between Rising Costs and Limited Budgets. <i>Frontiers in Public Health</i> , <b>2018</b> , 6, 328	6	68
5	Assessing the effectiveness and cost-effectiveness of drug intervention programs: UK case study. <i>Journal of Addictive Diseases</i> , <b>2017</b> , 36, 5-13	1.7	4
4	An assessment of the impact of pharmacogenomics on health disparities: a systematic literature review. <i>Pharmacogenomics</i> , <b>2017</b> , 18, 1541-1550	2.6	13
3	Adaptive Pathways: Possible Next Steps for Payers in Preparation for Their Potential Implementation. <i>Frontiers in Pharmacology</i> , <b>2017</b> , 8, 497	5.6	26
2	PayersViews of the Changes Arising through the Possible Adoption of Adaptive Pathways. <i>Frontiers in Pharmacology</i> , <b>2016</b> , 7, 305	5.6	44
1	Evaluating the use of plerixafor in stem cell mobilisation - an economic analysis of the PHANTASTIC trial. <i>Journal of Clinical Apheresis</i> , <b>2016</b> , 31, 434-42	3.2	10